We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Corticosteroid

    Health

    Study Questions Effectiveness of Budesonide for Preterm Infants with BPD

    A recent study from the Royal Women’s Hospital reveals that combining budesonide with surfactant may not significantly improve survival rates free from bronchopulmonary dysplasia (BPD) in extremely preterm infants. Published in JAMA, the PLUSS trial involved over 1,000 infants and highlights the complexities of treating BPD, a common respiratory condition in preterm babies. Further research is essential to refine treatment protocols and enhance neonatal care.

    Posted on Jhon
    Tech/Science

    Promising Results from BATURA Trial for New Asthma Medication Airsupra

    Avillion Life Sciences Ltd has announced promising results from the Phase IIIb BATURA trial, showcasing AstraZeneca’s inhaled medication Airsupra. This trial highlights a significant reduction in severe asthma exacerbations for patients with intermittent or mild persistent asthma, marking a potential breakthrough in asthma treatment. The Independent Data Monitoring Committee recommended an early halt due to the overwhelming efficacy observed, emphasizing the urgent need for effective asthma management solutions.

    Posted on Jhon
    Health

    Study Warns of Risks from Long-Term Use of Oral Corticosteroids for Atopic Dermatitis

    A recent study in JAMA Network Open reveals that prolonged use of oral corticosteroids for atopic dermatitis can increase the risk of adverse events. Conducted by Dr. Yong Hyun Jang, the research analyzed over 164,000 cases and recommends limiting corticosteroid treatment to 90 days to mitigate potential risks. This study emphasizes the importance of careful treatment duration in managing atopic dermatitis and may influence future clinical guidelines.

    Posted on Jhon
    Health

    Study Finds No Adverse Cardiovascular Effects in Adults Whose Mothers Received Corticosteroids During Pregnancy

    A recent study in Auckland, New Zealand, reveals no adverse cardiovascular health effects in adults whose mothers received corticosteroids during pregnancy 50 years ago. The study contradicts potential risks identified in animal studies, providing reassurance on the safety of corticosteroid use. Ongoing research explores the benefits of steroid treatments in preventing birth complications and lung diseases in newborns.

    Posted on Jhon